DDInter899 DDInter1680
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved
The New York City Board of Health strain of _Vaccinia_ is a viral strain used as a component of some smallpox vaccinations. ACAM2000, a percutaneously administered smallpox vaccine that was approved by the FDA in 2007, contains live antigens of this strain.
Smallpox (Vaccinia) Vaccine, Live {u} may lead to a major life threatening interaction when taken with {v} Cladribine
Smallpox (Vaccinia) Vaccine, Live {u} may lead to a major life threatening interaction when taken with {v} Risankizumab
Smallpox (Vaccinia) Vaccine, Live may lead to a major life threatening interaction when taken with Cladribine
Smallpox (Vaccinia) Vaccine, Live may lead to a major life threatening interaction when taken with Risankizumab